Preview

Атеротромбоз

Расширенный поиск

ОПЫТ 13-ЛЕТНЕЙ КОМБИНИРОВАННОЙ ГИПОЛИПИДЕМИЧЕСКОЙ ТЕРАПИИ СТАТИНАМИ С ФЕНОФИБРАТОМ У ПАЦИЕНТА ПОЖИЛОГО ВОЗРАСТА ОЧЕНЬ ВЫСОКОГО СЕРДЕЧНОСОСУДИСТОГО РИСКА

https://doi.org/10.21518/2307-1109-2013-2-26-37

Полный текст:

Аннотация

.

Об авторах

З. Г. Лугинова
Лаборатория клинической липидологии, ФГБУ РКНПК Минздрава России
Россия


А. Б. Блохин
ФГБУ «Поликлиника № 3» Управления делами Президента РФ
Россия


Е. Ю. Соловьева
Лаборатория клинической липидологии, ФГБУ РКНПК Минздрава России
Россия


А. В. Сусеков
Лаборатория клинической липидологии, ФГБУ РКНПК Минздрава России
Россия


Список литературы

1. Catapano A., Reiner Z., De Backer G. et al. EAS/EAS Guidelines for the management of dyslipidemias. The Task Force for the management of dyslipideamias of the Europea Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)//Atherosclerosis. 2011. P. 1–44.

2. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)//Eur. J. Prev. Cardiol. 2012. № 19 (4). P. 585–667. Epub. 2012 Jul.

3. Клинические рекомендации «Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза» (V пересмотр). 2012.

4. Chapman M. J., Ginsberg H. N., Amarenco P. et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management//Eur. Heart. J. 2011. № 32 (11). P. 1345–1361.

5. Robinson J. G. et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk//J. Am. Coll. Cardiol. 2009. № 53. P. 316–322.

6. Nitiyanant W., Sritara P., Deerochanawong C. et al. Lipid treatment assessment project II in Thailand (LTAP-II Thailand)//J. Med. Assoc. Thai. 2008. Vol. 91. № 6. Р. 836–845.

7. Fruchart J. C., Sacks F., Hermans M. P. et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia//Am. J. Cardiology. 2008. № 17. 102 (10 Suppl). P. 1–34.

8. Sachdeva А., Cannon C. P., Deedwania P. C., Labresh K. A. et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines//Am. Heart. J. 2009. № 157. P. 111–117.

9. Assmann G., Schulte H., Seedorf U. et al. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study// Int. J. Obesity. 2008. № 32. P. 11–16.

10. Wiesbauer F., Blessberger H., Azar D., Goliasch G. et al. Familial-combined hyperlipidemiya in very young myocardial infarction survivors (<or=40 age)//Eur. Heart. J. 2009. № 30 (9). P. 1073–1079.

11. Franssen R. et al. Diabetes, obesity, metabolism. 2009. № 11 (2). P. 89–94.

12. The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes//N. Engl. J. Med. 2011. № 364. P. 818–828.

13. Grundy S. M., Vega G. L., Yuan Z. et al. Effectiveness and tolerability of simvsatatin plus fenofibrate for combined hyperlipideamia (the SAFARI trial)// Am. J. Cardiol. 2006. № 98 (3). P. 427–428.

14. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial//Lancet. 2005. № 366. P. 1849–1861.

15. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo controlled trial in 25,673 highrisk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment//Eur. Heart. J. 2013.

16. Michos E. D., Sibley C. T., Baer J. T., Blaha M. J., Blumenthal R. S. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Inter vention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials//J. Am. Coll. Cardiol. 2012. № 59. P. 2058–2064.

17. Standards of medical care for patients in diabetes – 2012//Diabetes Care. 2012. Vol. 35. (suppl. 1).

18. HandelsmanY. et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice//Endocr. Pract. 2011. № 17 (suppl 2).

19. Gæde P., Vedel P., Parving H.-H., Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: the Steno type 2 randomised study//Lancet. 1999. № 353. P. 617–622.

20. Hansson L., Zanchetti A., Carruthers S. G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertention: rincipal results of the hypertension optimal treatment (HOT) randomized trial. HOT study Group//Lancet. 1998. № 351. P. 1755–1762.

21. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension//Eur. Heart. J. 2013.

22. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The diabetes Control and Complications Trial Research Group//N. Engl. J. Med. 1993. № 329. P. 977–986.

23. Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvaskular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study// Diabetes Res. Clin. Pract. 1995. № 28. P. 103–117.

24. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes//N. Engl. J. Med. 2008. № 358. P. 2560–2572.

25. Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes//N. Engl. J. 2009. № 360. P. 129–139.

26. Дедов И. И., Шестакова М. В., Аметов А. С. и др. Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии СД 2-го типа//Сахарный диабет. 2011. № 4. С. 6–17.

27. Сусеков А. В. Холестерин липопротеинов низкой плотности (ХС ЛНП) и ремнантный холестерин неЛВП – нужна ли рокировка для оценки сердечно-сосудистого риска?//Медицинский совет. 2013. № 9. C. 50–55.

28. Grundy S., Arai H., Barter P., Bersot T., Betteridge J., Carmena R., Cuevas A., Davidson M., Genest J., Kasaniemi A., Sadikot S., Santos R., Susekov A., Sy R., Tokgozogly L., Watts G., Zhao D. An International Atherosclerosis Society Position Paper: Global Recommendation for the Management of Dyslipideamia. Full Report. www.athero.org.

29. ESC Guidelines on diabetes, pre-diabetes and cardiovascular disease developed in collaboration with the EASD. The Task Force on diabetes, prediabetes and cardiovascular diseases of the European Association for the Study of Diabetes (EASD).

30. Martin S. S., Blaha M. J., Elshazly M. B., Brinton E. A. et al. Friedewald Estimated versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications//J. Am. Coll. Cardiol. 2013.


Для цитирования:


Лугинова З.Г., Блохин А.Б., Соловьева Е.Ю., Сусеков А.В. ОПЫТ 13-ЛЕТНЕЙ КОМБИНИРОВАННОЙ ГИПОЛИПИДЕМИЧЕСКОЙ ТЕРАПИИ СТАТИНАМИ С ФЕНОФИБРАТОМ У ПАЦИЕНТА ПОЖИЛОГО ВОЗРАСТА ОЧЕНЬ ВЫСОКОГО СЕРДЕЧНОСОСУДИСТОГО РИСКА. Атеротромбоз. 2013;(2):72-80. https://doi.org/10.21518/2307-1109-2013-2-26-37

For citation:


Лугинова З.Г., Блохин А.Б., Соловьева Е.Ю., Сусеков А.В. . Atherothrombosis Journal. 2013;(2):72-80. (In Russ.) https://doi.org/10.21518/2307-1109-2013-2-26-37

Просмотров: 325


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)